Insider Selling: Enfusion, Inc. (NYSE:ENFN) Insider Sells 18,241 Shares of Stock

Enfusion, Inc. (NYSE:ENFN) insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $8.11, for a total transaction of $147,934.51. Following the completion of the transaction, the insider now owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Bronwen Bastone also recently made the following trade(s):

• On Tuesday, June 18th, Bronwen Bastone sold 10,539 shares of Enfusion stock. The shares were sold at an average price of $8.17, for a total transaction of $86,103.63.

Enfusion Price Performance

Shares of Enfusion stock opened at $8.36 on Wednesday. Enfusion, Inc. has a 1 year low of $7.52 and a 1 year high of $11.56. The firm has a market cap of $1.07 billion, a PE ratio of 278.76, a PEG ratio of 1.93 and a beta of 0.96. The company has a 50 day simple moving average of $9.11 and a two-hundred day simple moving average of $9.08.

Enfusion (NYSE:ENFN) last announced its earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.05). Enfusion had a net margin of 1.40% and a return on equity of 6.60%. The company had revenue of $48.05 million for the quarter, compared to the consensus estimate of $47.67 million. During the same quarter in the previous year, the firm earned $0.04 earnings per share. As a group, research analysts anticipate that Enfusion, Inc. will post 0.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

ENFN has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on shares of Enfusion in a research report on Friday, May 10th. They issued an “overweight” rating and a $11.00 price objective for the company. The Goldman Sachs Group lowered shares of Enfusion from a “neutral” rating to a “sell” rating and cut their price objective for the company from $9.00 to $8.00 in a research report on Wednesday, February 28th. Finally, Bank of America raised their price objective on shares of Enfusion from $8.00 to $9.00 and gave the company an “underperform” rating in a research report on Wednesday, March 13th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Enfusion has a consensus rating of “Hold” and an average price target of $9.33.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC purchased a new position in shares of Enfusion during the first quarter worth approximately $44,000. Tower Research Capital LLC TRC raised its stake in shares of Enfusion by 680.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 9,894 shares of the company’s stock worth $96,000 after acquiring an additional 8,627 shares in the last quarter. Barclays PLC raised its stake in shares of Enfusion by 29.0% during the third quarter. Barclays PLC now owns 10,809 shares of the company’s stock worth $96,000 after acquiring an additional 2,430 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Enfusion during the first quarter worth approximately $102,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Enfusion during the first quarter worth approximately $109,000. 81.05% of the stock is owned by hedge funds and other institutional investors.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.